Project Grant R01CA292937
Award Date
4/1/25
Completion Date
3/31/30
Dollars Obligated
$698K
Federal Agency
National Cancer Institute
Federal Grant Program
93.396
Assistance Type
Project Grant
Place of Performance
Pennsylvania, USA
Similar Awards
This Project Grant award from the National Cancer Institute's Cancer Biology Research program (CFDA 93.396) supports research to assess the role of the DCAF15 protein in acute myeloid leukemia (AML). The primary objectives are to: (A) decipher the biological function of DCAF15 in myeloid development and leukemia in vivo, (B) investigate the role of cohesin acetylation in AML pathogenesis, and (C) develop small molecule degraders targeting DCAF15. The award of $483,760 was granted to The...
This $227,906 Project Grant award from the National Cancer Institute's Cancer Biology Research program (CFDA 93.396) will support the development of a novel technology for spatially resolved co-mapping of epigenomic, transcriptomic, and proteomic profiles in formalin-fixed paraffin-embedded (FFPE) tumor tissue samples at the cellular level. The project aims to (1) develop spatial epigenome sequencing to measure gene expression and epigenetic cell state markers directly in FFPE tissues, and...
This $1,096,866 project grant was awarded on August 15, 2023 by the Defense Health Agency under the Department of Defense's Military Medical Research and Development program (CFDA 12.420). The grant, titled "TARGETING BRANCHED CHAIN AMINO ACIDS IN KIDNEY CANCER," will be carried out by The Trustees of the University of Pennsylvania, doing business as the Clinical Practices of the University of Pennsylvania, over a 3-year period ending on August 14, 2026. The funding supports...
This federal Project Grant award from the National Cancer Institute's Cancer Biology Research program (CFDA 93.396) provides $249,000.00 to the Trustees of the University of Pennsylvania to conduct research aimed at decoding the evolution and progression of glioma, an incurable brain cancer. The research plan involves developing novel single-cell technologies to concurrently profile the transcriptome, epigenome, and genome of glioma cells. This multi-dimensional profiling will help define how...
This federal Project Grant award of $436,431 from the National Cancer Institute's Cancer Biology Research program (CFDA 93.396) supports research to target metabolic crosstalk in pancreatic ductal adenocarcinoma (PDA). The University of California, Irvine is the prime awardee, conducting fundamental investigations into mechanisms that maintain cancer cell heterogeneity and metabolic symbiosis in PDA tumors. The research aims to identify oncogenic and stress pathways that can be targeted to...
This federal Project Grant award, totaling $552,763, was provided by the National Cancer Institute (NCI) under the Cancer Treatment Research program (CFDA 93.395) to The Trustees of the University of Pennsylvania, doing business as the Clinical Practices of the University of Pennsylvania.
The grant funds research aimed at assessing the therapeutic potential of newly developed KAT6 inhibitors (KAT6is) as monotherapy and in combination with targeted therapy drugs for the treatment of high-grade...
The Johns Hopkins University was awarded a $431,561 Project Grant from the National Cancer Institute (NCI) under the Cancer Treatment Research program (CFDA 93.395) to conduct research aimed at elucidating the role of the HMGA1 chromatin regulator in pancreatic ductal adenocarcinoma (PDAC) progression and the tumor microenvironment (TME). The research project seeks to precisely define HMGA1-dependent mechanisms in PDAC tumor progression using mouse models and primary human tumors, as well as...
This $160,642 Project Grant award from the National Cancer Institute (CFDA 93.398 - Cancer Research Manpower program) supports research at the University of Pennsylvania to develop novel epigenome editing technologies and uncover genes involved in chimeric antigen receptor (CAR) T cell exhaustion. The proposed work aims to create "split-engineered CRISPR/dCas9-guided epigenome editors" that can inducibly activate target genes to study the dynamic epigenetic landscape of chronically...
The National Institute of General Medical Sciences (NIGMS) awarded a $406,250 Project Grant under the Biomedical Research and Research Training program (CFDA 93.859) to The Trustees of the University of Pennsylvania, doing business as the Clinical Practices of the University of Pennsylvania. The grant, which runs from August 15, 2024 to July 31, 2029, supports research to mechanistically determine how growth and adaptive signaling cascades interact by: 1) mapping the post-transcriptional...
This Project Grant award of $1,625,000 from the U.S. Department of Defense's Military Medical Research and Development program (CFDA 12.420) supports in-vivo mechanistic characterization of the angiogenic immune checkpoint in liver cancer at the Trustees of the University of Pennsylvania. The research aims to advance scientific understanding and develop solutions for this important health challenge. The award commenced on September 1, 2023 and is scheduled for completion by August 31, 2027....